Immuron Commences US Non-Deal Institutional Investor Roadshow
August 15 2017 - 9:15AM
Australian microbiome biopharmaceutical company Immuron Limited
(ASX:IMC) (NASDAQ:IMRN) is pleased to release to shareholders and
investors its latest Company Update presentation ahead of a
comprehensive roadshow to investment institutions, analysts and
shareholders in the United States, where interim-CEO Dr. Jerry
Kanellos will be updating on recent trials progress and upcoming
milestones.
Dr. Kanellos will be meeting with key US fund
managers to highlight the current position and strength of
Immuron’s patent portfolio, the Company’s multiple clinical trials
which are underway in the areas of NASH, ASH, C Clostridium
Difficile Infection, and the increasing traction Immuron’s Travelan
product, for the prevention of travellers’ diarrhea, is gaining in
both the Australian and US market.
Immuron’s newly appointed Interim-CEO Dr. Jerry
Kanellos highlighted;
“We have some very exciting times ahead at
Immuron as many of our projects approach critical milestones and
targets. Following the initial share price fluctuations after our
NASDAQ listing, it’s important than we now firm up our investor
base and showcase Immuron’s amazing technology platform to those
who are yet to see and understand the Immuron story.
I’m truly honored to be able to present Immuron
to the market and explain the Company value proposition to US
institutional investors as we move into the next phase of our
lifecycle.”
A copy of the roadshow presentation is available
by clicking on the following
link:http://www.globenewswire.com/NewsRoom/AttachmentNg/fb410551-0f70-4e66-9a2b-4335150b6a13
ABOUT IMMURON:Immuron Ltd
(ASX:IMC) is a biopharmaceutical company focused on developing and
commercialising oral immunotherapeutics for the treatment of many
gut mediated diseases. Immuron has a unique and safe technology
platform that enables a shorter development therapeutic cycle. The
Company currently markets and sells Travelan® for the prevention of
travellers’ diarrhea whilst its lead product candidate IMM-124E is
in Phase 2 clinical trials for NASH and ASH. These products
together with the Company’s other preclinical immunotherapy
pipeline products targeting immune-related diseases currently under
development, will meet a large unmet need in the market. For more
information visit: http://www.immuron.com
FORWARD-LOOKING
STATEMENTS:Certain statements made in this release are
forward-looking statements and are based on Immuron’s current
expectations, estimates and projections. Words such as
“anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,”
“estimates,” “guidance” and similar expressions are intended to
identify forward-looking statements. Although Immuron believes the
forward-looking statements are based on reasonable assumptions,
they are subject to certain risks and uncertainties, some of which
are beyond Immuron’s control, including those risks or
uncertainties inherent in the process of both developing and
commercialising technology. As a result, actual results could
materially differ from those expressed or forecasted in the
forward-looking statements. The forward-looking statements made in
this release relate only to events as of the date on which the
statements are made. Immuron will not undertake any obligation to
release publicly any revisions or updates to these forward-looking
statements to reflect events, circumstances or unanticipated events
occurring after the date of this release except as required by law
or by any appropriate regulatory authority.
COMPANY CONTACT:
Dr. Jerry Kanellos
Interim-Chief Executive Officer
AUS Ph: +61 (0)3 9824 5254
jerrykanellos@immuron.com
US INVESTORS RELATIONS:
Jon Cunningham
RedChip Companies, Inc.
US Ph: +1 (407) 644 4256, (ext. 107)
jon@redchip.com
AUSTRALIA INVESTORS RELATIONS:
Peter Taylor
NWR Communications
AUS Ph: +61 (0)4 1203 6231
peter@nwrcommunications.com.au
US PUBLIC RELATIONS:
Eric Fischgrund
FischTank - Marketing and PR
US Ph: +1 (646) 699 1148
eric@fischtankpr.com
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immuron (NASDAQ:IMRN)
Historical Stock Chart
From Apr 2023 to Apr 2024